CKD Drug Hit Phase III Endpoints Yet Rejected by FDA
Shares of Ardelyx, Inc. have fallen nearly 13% in premarket trading after the U.S. FDA rejected the company's chronic kidney disease drug, tenapanor.
The Home of the Life Sciences Industry
Explore Latest News
Annovis Bio’s AD/PD Therapy Reduces Cytotoxic Cascade in Phase IIa Trials
Annovis Bio’s therapy for Alzheimer’s disease is fast-acting and has the potential for Alzheimer’s patients to significantly improve cognition and motor function, according to data presented at the Alzheimer’s Association International Conference® 2021 (AAIC®), held July 26th through 30th.
- Sponsored | The essential guide to drug commercialization: A manufacturer’s handbook for selecting solutions and partners
- Research Shows COVID-19 Victims Suffer Some Degree of Brain Damage
- CDC Cracks Down on Masks Again and Warns Delta Is As infectious As Chickenpox
- EAPs, Regulatory Flexibility Discussed As House Committee Meets On ALS
- Profiling the Risk-Benefit Analysis of COVID-19 Vaccines for Kids
Get personalized job alerts
Create a job alert and receive custom job recommendations straight to your inbox.
Employers
Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.